ZTS

Systematic screening of Zoetis Inc reveals a distinctive profitability profile within the animal health pharmaceutical sector, characterized by exceptional return metrics despite recent price compression. The stock trades at a P/E ratio of 11.77, representing a sharp discount from its 52-week high of $172.23, while the current price of $77.72 sits near the lower bound of its annual range. This valuation contraction creates an unusual disconnect: the company generates ROE of 62.41% and ROA of 17.54%, yet trades at multiples typically associated with value situations rather than high-return businesses.

The fundamental screening highlights several operational strengths:

• Margin structure demonstrates exceptional pricing power, with gross margin of 71.82% translating to net margin of 27.79%, indicating efficient conversion through the income statement
• Operating margin of 34.79% reflects disciplined cost management within specialized veterinary pharmaceutical operations
• Current ratio of 3.03 provides substantial liquidity cushion for operational flexibility
• Beta of 0.81 offers defensive characteristics relative to broader equity indices

Risk factors identified through quantitative analysis include elevated leverage, with debt-to-equity of 2.72 suggesting aggressive capital structure deployment. Revenue growth of 2.4% year-over-year indicates maturing market dynamics, while EPS growth of 8.39% demonstrates margin expansion compensating for top-line deceleration. The P/B ratio of 16.65 implies significant intangible asset intensity, common among pharmaceutical franchises but creating balance sheet concentration risk.

Positioning relative to human pharmaceutical peers LLY, JNJ, and MRK reveals specialization advantages in the companion animal and livestock segments, though at substantially smaller scale given the $50.9B market capitalization.